The Fort Worth Press - Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

USD -
AED 3.673042
AFN 70.194145
ALL 87.342841
AMD 388.911102
ANG 1.80229
AOA 917.000367
ARS 1126.879559
AUD 1.560306
AWG 1.8
AZN 1.70397
BAM 1.737794
BBD 2.017593
BDT 121.409214
BGN 1.737794
BHD 0.376738
BIF 2972.677596
BMD 1
BND 1.297259
BOB 6.904794
BRL 5.648504
BSD 0.999245
BTN 85.280554
BWP 13.549247
BYN 3.27007
BYR 19600
BZD 2.007197
CAD 1.39395
CDF 2872.000362
CHF 0.832049
CLF 0.024361
CLP 934.834955
CNY 7.237304
CNH 7.24022
COP 4248.70052
CRC 507.174908
CUC 1
CUP 26.5
CVE 97.974144
CZK 22.179804
DJF 177.937714
DKK 6.632104
DOP 58.79426
DZD 133.028566
EGP 50.592208
ERN 15
ETB 134.071527
EUR 0.888604
FJD 2.269204
FKP 0.751681
GBP 0.751965
GEL 2.74504
GGP 0.751681
GHS 13.139633
GIP 0.751681
GMD 71.503851
GNF 8653.427518
GTQ 7.685815
GYD 209.667244
HKD 7.778704
HNL 25.959394
HRK 6.698104
HTG 130.498912
HUF 359.260388
IDR 16550.45
ILS 3.54213
IMP 0.751681
INR 85.408504
IQD 1308.987516
IRR 42100.000352
ISK 130.610386
JEP 0.751681
JMD 158.834244
JOD 0.709304
JPY 145.56504
KES 129.148341
KGS 87.450384
KHR 4000.177707
KMF 436.503794
KPW 900.000002
KRW 1396.160383
KWD 0.306704
KYD 0.832734
KZT 515.695944
LAK 21600.248789
LBP 89531.298592
LKR 298.556133
LRD 199.848949
LSL 18.174153
LTL 2.95274
LVL 0.60489
LYD 5.476032
MAD 9.244125
MDL 17.126483
MGA 4495.979386
MKD 54.671465
MMK 2099.733149
MNT 3573.792034
MOP 8.005864
MRU 39.809854
MUR 45.710378
MVR 15.403739
MWK 1732.640277
MXN 19.448039
MYR 4.297039
MZN 63.903729
NAD 18.174153
NGN 1607.110377
NIO 36.767515
NOK 10.37045
NPR 136.448532
NZD 1.692477
OMR 0.384771
PAB 0.999245
PEN 3.630192
PGK 4.147674
PHP 55.367038
PKR 281.409214
PLN 3.765161
PYG 7988.804478
QAR 3.646186
RON 4.549804
RSD 104.145009
RUB 83.34444
RWF 1436.403216
SAR 3.750904
SBD 8.343881
SCR 14.203038
SDG 600.503676
SEK 9.708504
SGD 1.298604
SHP 0.785843
SLE 22.750371
SLL 20969.483762
SOS 571.060465
SRD 36.702504
STD 20697.981008
SVC 8.743169
SYP 13001.854971
SZL 18.166067
THB 32.971038
TJS 10.342085
TMT 3.51
TND 3.007952
TOP 2.342104
TRY 38.730504
TTD 6.788396
TWD 30.261404
TZS 2695.455151
UAH 41.510951
UGX 3657.203785
UYU 41.769959
UZS 12870.407393
VES 92.71499
VND 25978.5
VUV 121.00339
WST 2.778525
XAF 582.839753
XAG 0.03055
XAU 0.0003
XCD 2.70255
XDR 0.724866
XOF 582.839753
XPF 105.966502
YER 244.450363
ZAR 18.214104
ZMK 9001.203587
ZMW 26.305034
ZWL 321.999592
  • RBGPF

    65.2700

    65.27

    +100%

  • NGG

    0.5100

    70.69

    +0.72%

  • GSK

    -0.2500

    36.62

    -0.68%

  • SCS

    -0.0200

    10.46

    -0.19%

  • CMSC

    -0.0500

    22.06

    -0.23%

  • AZN

    0.2700

    67.57

    +0.4%

  • RELX

    0.3486

    53.85

    +0.65%

  • BTI

    -1.6600

    41.64

    -3.99%

  • RIO

    0.8000

    59.98

    +1.33%

  • CMSD

    0.0100

    22.34

    +0.04%

  • RYCEF

    0.0500

    10.55

    +0.47%

  • JRI

    0.0300

    12.98

    +0.23%

  • BP

    1.1800

    29.77

    +3.96%

  • BCC

    -0.9600

    88.62

    -1.08%

  • VOD

    0.0500

    9.3

    +0.54%

  • BCE

    0.4800

    22.71

    +2.11%

Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its first quarter 2025 financial results, and provide a corporate update.

Text size:

A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.

The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Media Contacts

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.



View the original press release on ACCESS Newswire

A.Williams--TFWP